Accountancy

AstraZeneca-Alexion deal pushes global M&A over the $1tn mark for second consecutive quarter

The deal between AstraZeneca and Alexion comes amid a slew of M&A megadeals. Deals recorded since July total $2.1tn, according to Refinitiv data

British drug giant AstraZeneca’s $38.8bn bid for Boston-based pharmaceutical company Alexion pushed deal values to $1tn in the fourth quarter
British drug giant AstraZeneca’s $38.8bn bid for Boston-based pharmaceutical company Alexion pushed deal values to $1tn in the fourth quarter Photo: Getty Images

Mergers and acquisitions recorded in the fourth quarter of 2020 reached $1tn, making it the second consecutive trillion-dollar quarter, according to Refinitiv.

In a 14 December statement, the data provider said that the quarter was boosted by British drug giant AstraZeneca’s $38.8bn bid for Boston-based pharmaceutical company Alexion. Since July, the deals struck have totalled $2.1tn in value, making it the second highest second-half total since Refinitiv’s records started in the 1970s.

WSJ Logo
Bank of New York Mellon Approached Northern Trust to Discuss Potential MergerExternal link

Bank of New York Mellon Approached Northern Trust to Discuss Potential Merger